Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment

Patent metadata

Field	Value
Publication number	US-2016143906-A1
Application number	US-201615010115-A
Country	US
Kind code	A1
Filing date	Jan 29, 2016
Priority date	May 10, 2013
Publication date	May 26, 2016
Grant date	—

Abstract

The present invention relates to a beneficial treatment of tumours in patients suffering from NSCLC, and to a clinical marker useful as predictive variable of the responsiveness of tumours in patients suffering from NSCLC. The present invention further relates to a method for selecting patients likely to respond to a given therapy, wherein said method optionally comprises the use of a specific clinical marker. The present invention further relates to a method for delaying disease progression and/or prolonging patient survival of NSCLC patients, wherein said method comprises the use of a specific clinical marker.

First claim

1 . A method for the treatment of non-small cell lung cancer in a patient who has received prior treatment with an anti-tumour therapy other than with nintedanib, which method comprises treating said patient with a treatment regimen comprising the administration of nintedanib or a pharmaceutically acceptable salt thereof, wherein the patient to be treated is selected for treatment on the basis of having shown progression of the cancer within a period of 9 months or less after the initiation of said prior treatment.

2 . The method in accordance with claim 1 , wherein said prior treatment with an anti-tumour therapy other than with nintedanib is a monotherapeutic treatment with a platinum compound, or a combination treatment of a platinum compound with one or more further therapeutic agents other than nintedanib.

3 . The method in accordance with claim 1 , wherein said pharmaceutically acceptable salt is nintedanib esylate.

4 . The method in accordance with claim 1 , wherein the treatment regimen comprising the administration of nintedanib or a pharmaceutically acceptable salt thereof is a combination treatment regimen with an anti-cancer drug selected from the group consisting of docetaxel, paclitaxel, pemetrexed, pralatrexate, and pharmaceutically acceptable salts thereof.

Assignees

• Boehringer Ingelheim Int

Inventors

• Gaschler-Markefski Birgit
• Kaiser Rolf

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/496 Primary

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title